# Antisense Oligonucleotides and RNA Therapeutics

## Introduction

RNA therapeutics represent a rapidly expanding class of treatments that target gene expression at the RNA level rather than the protein level. Antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and mRNA therapeutics each offer distinct mechanisms for modulating gene expression and have yielded multiple FDA-approved treatments for genetic diseases.

## Antisense Oligonucleotides

### Mechanism of Action

ASOs are short (15-25 nucleotide), single-stranded, chemically modified DNA or RNA analogs that bind to target pre-mRNA or mRNA through Watson-Crick base pairing. They function through multiple mechanisms of action. RNase H-mediated degradation occurs when the ASO-mRNA duplex is recognized by RNase H, which cleaves the mRNA strand, effectively silencing the gene. Splice modulation involves ASOs masking splice sites or regulatory elements to alter pre-mRNA splicing, promoting exon skipping or exon inclusion. Translation blocking involves steric blockade of ribosome binding without mRNA degradation.

### Chemical Modifications

Several chemical modifications enhance ASO therapeutic properties. The phosphorothioate (PS) backbone substitutes sulfur for a non-bridging oxygen in the phosphodiester bond, increasing nuclease resistance and protein binding. The 2'-O-methoxyethyl (2'-MOE) sugar modification improves binding affinity and reduces toxicity. Locked nucleic acid (LNA) is a bicyclic sugar modification with very high binding affinity. Phosphorodiamidate morpholino oligomers (PMOs) have an uncharged backbone with a morpholine ring and an excellent safety profile, used in Duchenne muscular dystrophy exon-skipping therapies. Peptide nucleic acids (PNAs) have a synthetic backbone resistant to nucleases but limited clinical use to date.

### Pharmacokinetics

ASOs are administered via subcutaneous injection, intrathecal injection, or intravenous infusion depending on the target tissue. PS-modified ASOs distribute broadly with liver and kidney accumulation. CNS-targeted ASOs require intrathecal administration, as exemplified by nusinersen for SMA. Long tissue half-lives of weeks to months allow infrequent dosing schedules.

![Diagram illustrating ASO mechanisms of action including RNase H-mediated degradation, splice modulation for exon skipping, and translational blockade](images/aso-mechanisms.png)

## FDA-Approved ASO Therapies for Genetic Diseases

### Nusinersen (Spinraza, 2016)

Nusinersen is a splice-modulating ASO for spinal muscular atrophy. It targets SMN2 pre-mRNA to promote inclusion of exon 7, increasing full-length SMN protein production. Administered intrathecally with loading doses followed by maintenance every 4 months, it dramatically improved motor function and survival in SMA type 1 infants and is also effective in later-onset SMA. It was the first FDA-approved treatment for SMA.

### Eteplirsen (Exondys 51, 2016) and Related DMD Therapies

Eteplirsen and related therapies are PMO-based exon-skipping ASOs for Duchenne muscular dystrophy. They skip specific exons to restore the reading frame, producing a truncated but partially functional dystrophin protein similar to that seen in Becker muscular dystrophy. Eteplirsen skips exon 51, making approximately 13% of DMD patients eligible. Additional therapies include golodirsen and viltolarsen for exon 53 skipping and casimersen for exon 45 skipping. These require weekly IV infusion, produce modest dystrophin levels, and received accelerated approval with clinical benefit still debated.

### Inotersen (Tegsedi, 2018) and Eplontersen (Wainua, 2023)

These ASOs target TTR mRNA for hereditary transthyretin amyloidosis (hATTR) through RNase H-mediated degradation of TTR mRNA, reducing circulating transthyretin protein. Eplontersen is a ligand-conjugated ASO (GalNAc-conjugated) with improved liver targeting and convenient monthly dosing.

### Tofersen (Qalsody, 2023)

Tofersen targets SOD1 mRNA for SOD1-associated ALS via intrathecal administration. It reduces neurofilament light chain levels and received accelerated approval.

## Small Interfering RNA (siRNA) Therapeutics

### Mechanism

siRNAs are double-stranded RNA molecules of approximately 21 nucleotides that harness the endogenous RNA interference (RNAi) pathway. The guide strand is loaded into the RNA-induced silencing complex (RISC), which cleaves complementary target mRNA via Argonaute 2. The mechanism is highly potent because it is catalytic, allowing a single siRNA molecule to silence multiple mRNA molecules. Unlike ASOs, siRNAs do not alter pre-mRNA splicing and function strictly as gene silencing agents.

### GalNAc Conjugation

N-acetylgalactosamine (GalNAc) conjugation enables targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). This conjugation allows subcutaneous administration with potent, durable liver-targeted gene silencing. Dosing intervals of every 3-6 months are achievable for some GalNAc-siRNAs, representing a remarkable advance in convenience. The current limitation is restriction to liver-expressed targets.

| Platform | Mechanism | Structure | Route | Duration of Effect | Key Approved Examples |
|---|---|---|---|---|---|
| ASO (RNase H) | mRNA degradation via RNase H | Single-stranded, 15–25 nt | SC, IT, IV | Weeks–months | Inotersen (hATTR), tofersen (SOD1-ALS) |
| ASO (splice modulation) | Exon skipping/inclusion | Single-stranded PMO or 2'-MOE | SC, IT, IV | Weeks–months | Nusinersen (SMA), eteplirsen (DMD) |
| siRNA (RNAi) | RISC-mediated mRNA cleavage | Double-stranded, ~21 nt | SC (GalNAc) | 3–6 months | Patisiran, givosiran, inclisiran |
| mRNA therapeutic | Protein replacement | Modified mRNA in LNP | IV | Days–weeks | COVID vaccines; gene therapy (emerging) |

### FDA-Approved siRNA Therapies

Patisiran (Onpattro, 2018) was the first FDA-approved siRNA, targeting TTR for hATTR polyneuropathy via LNP-formulated IV infusion every 3 weeks. Givosiran (Givlaari, 2019) is a GalNAc-siRNA targeting ALAS1 for acute hepatic porphyria via monthly subcutaneous injection, dramatically reducing porphyria attacks. Lumasiran (Oxlumo, 2020) is a GalNAc-siRNA targeting HAO1 for primary hyperoxaluria type 1, reducing hepatic oxalate production. Inclisiran (Leqvio, 2021) is a GalNAc-siRNA targeting PCSK9 for hypercholesterolemia requiring only twice-yearly subcutaneous injection with significant LDL-C reduction. Vutrisiran (Amvuttra, 2022) is a GalNAc-siRNA targeting TTR for hATTR with quarterly subcutaneous injection, offering improved convenience over patisiran.

![Comparison table of approved ASO and siRNA therapies showing drug name, target, disease, mechanism, route, and dosing frequency](images/rna-therapeutics-approved.png)

## mRNA Therapeutics

### Beyond Vaccines

mRNA encoding therapeutic proteins can serve as protein replacement therapy. No nuclear entry is required because translation occurs in the cytoplasm. Transient expression lasting hours to days requires repeat dosing but avoids genomic integration risk. Lipid nanoparticle delivery, proven by COVID-19 mRNA vaccines, is being adapted for genetic disease applications.

### Emerging Applications

mRNA for enzyme replacement therapy is being explored for metabolic diseases currently treated with IV enzyme replacement, with trials in methylmalonic acidemia and propionic acidemia. mRNA for gene therapy provides transient expression of Cas9 for gene editing, as used in NTLA-2001 for hATTR. mRNA for rare protein deficiencies is under investigation for cystic fibrosis, ornithine transcarbamylase deficiency, and other conditions.

## Challenges and Future Directions

### Delivery Beyond the Liver

Current GalNAc and LNP platforms are primarily liver-tropic. Delivery to muscle, CNS, heart, and lung remains a major challenge for systemic RNA therapeutics. Emerging strategies include antibody-siRNA conjugates, exosomes, polymeric nanoparticles, and novel lipid formulations. Intrathecal delivery is effective for CNS targets but invasive, limiting patient acceptability for chronic conditions.

### Immunogenicity and Toxicity

ASOs can cause thrombocytopenia, hepatotoxicity, and injection site reactions. Some chemical modifications, particularly the PS backbone, activate complement and coagulation pathways. siRNAs can trigger innate immune responses through toll-like receptors, though chemical modifications minimize this. Chronic dosing raises questions about long-term toxicity that require ongoing pharmacovigilance.

### Cost and Access

RNA therapeutics are among the most expensive drugs available. Nusinersen costs approximately $750,000 in the first year and roughly $375,000 annually thereafter. Value-based pricing and outcomes-based agreements are being explored as sustainable payment models. Global access is severely limited by cost.

![Emerging RNA therapeutic modalities including circular RNA, aptamers, mRNA therapeutics, and next-generation delivery platforms](images/rna-therapeutics-future.png)

## Clinical Pearls

ASOs and siRNAs work through fundamentally different mechanisms: ASOs can modulate splicing (as with nusinersen) or degrade mRNA, while siRNAs exclusively silence gene expression through the RNAi pathway. GalNAc conjugation has transformed liver-targeted RNA therapeutics, enabling subcutaneous dosing at intervals of months, and extending this targeting paradigm to other tissues is the major translational frontier. Nusinersen for SMA demonstrated that early treatment, ideally presymptomatic, produces the best outcomes, reinforcing the importance of newborn screening for genetically treatable conditions. The growing portfolio of approved RNA therapeutics for genetic diseases represents a shift from protein-level to RNA-level intervention, complementing and potentially replacing traditional enzyme replacement therapies.

## References

1. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. *Cell Metabolism*. 2018;27(4):714-739.
2. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *New England Journal of Medicine*. 2017;377(18):1723-1732.
3. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *New England Journal of Medicine*. 2018;379(1):11-21.
4. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. *Nature Reviews Drug Discovery*. 2020;19(10):673-694.